Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study

Global Burden of Disease Cancer Collaboration

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Importance: Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data. Objective: To describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning. Evidence Review: We used the GBD study estimation methods to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs). Results are presented at the national level as well as by Socio-demographic Index (SDI), a composite indicator of income, educational attainment, and total fertility rate. We also analyzed the influence of the epidemiological vs the demographic transition on cancer incidence. Findings: In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority of cancer DALYs came from years of life lost (97%), and only 3% came from years lived with disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL) cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and 28.4 million DALYs), liver cancer (572000 deaths and 15.2 million DALYs), and stomach cancer (542000 deaths and 12.2 million DALYs). For women in 2017, the most common incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident cases), and colorectal cancer (819000 incident cases). The leading causes of cancer deaths and DALYs for women were breast cancer (601000 deaths and 17.4 million DALYs), TBL cancer (596000 deaths and 12.6 million DALYs), and colorectal cancer (414000 deaths and 8.3 million DALYs). Conclusions and Relevance: The national epidemiological profiles of cancer burden in the GBD study show large heterogeneities, which are a reflection of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. The GBD study can be used by policy makers and other stakeholders to develop and improve national and local cancer control in order to achieve the global targets and improve equity in cancer care.

Original languageEnglish
JournalJAMA Oncology
DOIs
Publication statusAccepted/In press - 1 Jan 2019

Fingerprint

Quality-Adjusted Life Years
Mortality
Incidence
Neoplasms
Skin Neoplasms
Bronchi
Global Burden of Disease
Lung Neoplasms
Demography
Cause of Death
Colorectal Neoplasms
Breast Neoplasms
United Nations
Birth Rate
Conservation of Natural Resources
Population Dynamics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{862813a57d494ea0b705547e5a6eeb29,
title = "Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study",
abstract = "Importance: Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data. Objective: To describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning. Evidence Review: We used the GBD study estimation methods to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs). Results are presented at the national level as well as by Socio-demographic Index (SDI), a composite indicator of income, educational attainment, and total fertility rate. We also analyzed the influence of the epidemiological vs the demographic transition on cancer incidence. Findings: In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority of cancer DALYs came from years of life lost (97{\%}), and only 3{\%} came from years lived with disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL) cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and 28.4 million DALYs), liver cancer (572000 deaths and 15.2 million DALYs), and stomach cancer (542000 deaths and 12.2 million DALYs). For women in 2017, the most common incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident cases), and colorectal cancer (819000 incident cases). The leading causes of cancer deaths and DALYs for women were breast cancer (601000 deaths and 17.4 million DALYs), TBL cancer (596000 deaths and 12.6 million DALYs), and colorectal cancer (414000 deaths and 8.3 million DALYs). Conclusions and Relevance: The national epidemiological profiles of cancer burden in the GBD study show large heterogeneities, which are a reflection of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. The GBD study can be used by policy makers and other stakeholders to develop and improve national and local cancer control in order to achieve the global targets and improve equity in cancer care.",
author = "{Global Burden of Disease Cancer Collaboration} and Christina Fitzmauric and Christina Fitzmaurice and Degu Abate and Naghmeh Abbasi and Hedayat Abbastabar and Foad Abd-Allah and Omar Abdel-Rahman and Ahmed Abdelalim and Amir Abdoli and Ibrahim Abdollahpour and Abdulle, {Abdishakur S.M.} and Abebe, {Nebiyu Dereje} and Abraha, {Haftom Niguse} and Abu-Raddad, {Laith Jamal} and Ahmed Abualhasan and Adedeji, {Isaac Akinkunmi} and Advani, {Shailesh M.} and Mohsen Afarideh and Mahdi Afshari and Mohammad Aghaali and Dominic Agius and Sutapa Agrawal and Ayat Ahmadi and Elham Ahmadian and Ehsan Ahmadpour and Ahmed, {Muktar Beshir} and Akbari, {Mohammad Esmaeil} and Tomi Akinyemiju and Ziyad Al-Aly and Alabdulkader, {Assim M.} and Fares Alahdab and Tahiya Alam and Alamene, {Genet Melak} and Alemnew, {Birhan Tamene T.} and Alene, {Kefyalew Addis} and Cyrus Alinia and Vahid Alipour and Aljunid, {Syed Mohamed} and Bakeshei, {Fatemeh Allah} and Almadi, {Majid Abdulrahman Hamad} and Amir Almasi-Hashiani and Ubai Alsharif and Shirina Alsowaidi and Nelson Alvis-Guzman and Erfan Amini and Saeed Amini and Amoako, {Yaw Ampem} and Zohreh Anbari and Anber, {Nahla Hamed} and Andrei, {Catalina Liliana}",
year = "2019",
month = "1",
day = "1",
doi = "10.1001/jamaoncol.2019.2996",
language = "English",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",

}

TY - JOUR

T1 - Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017

T2 - A Systematic Analysis for the Global Burden of Disease Study

AU - Global Burden of Disease Cancer Collaboration

AU - Fitzmauric, Christina

AU - Fitzmaurice, Christina

AU - Abate, Degu

AU - Abbasi, Naghmeh

AU - Abbastabar, Hedayat

AU - Abd-Allah, Foad

AU - Abdel-Rahman, Omar

AU - Abdelalim, Ahmed

AU - Abdoli, Amir

AU - Abdollahpour, Ibrahim

AU - Abdulle, Abdishakur S.M.

AU - Abebe, Nebiyu Dereje

AU - Abraha, Haftom Niguse

AU - Abu-Raddad, Laith Jamal

AU - Abualhasan, Ahmed

AU - Adedeji, Isaac Akinkunmi

AU - Advani, Shailesh M.

AU - Afarideh, Mohsen

AU - Afshari, Mahdi

AU - Aghaali, Mohammad

AU - Agius, Dominic

AU - Agrawal, Sutapa

AU - Ahmadi, Ayat

AU - Ahmadian, Elham

AU - Ahmadpour, Ehsan

AU - Ahmed, Muktar Beshir

AU - Akbari, Mohammad Esmaeil

AU - Akinyemiju, Tomi

AU - Al-Aly, Ziyad

AU - Alabdulkader, Assim M.

AU - Alahdab, Fares

AU - Alam, Tahiya

AU - Alamene, Genet Melak

AU - Alemnew, Birhan Tamene T.

AU - Alene, Kefyalew Addis

AU - Alinia, Cyrus

AU - Alipour, Vahid

AU - Aljunid, Syed Mohamed

AU - Bakeshei, Fatemeh Allah

AU - Almadi, Majid Abdulrahman Hamad

AU - Almasi-Hashiani, Amir

AU - Alsharif, Ubai

AU - Alsowaidi, Shirina

AU - Alvis-Guzman, Nelson

AU - Amini, Erfan

AU - Amini, Saeed

AU - Amoako, Yaw Ampem

AU - Anbari, Zohreh

AU - Anber, Nahla Hamed

AU - Andrei, Catalina Liliana

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Importance: Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data. Objective: To describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning. Evidence Review: We used the GBD study estimation methods to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs). Results are presented at the national level as well as by Socio-demographic Index (SDI), a composite indicator of income, educational attainment, and total fertility rate. We also analyzed the influence of the epidemiological vs the demographic transition on cancer incidence. Findings: In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority of cancer DALYs came from years of life lost (97%), and only 3% came from years lived with disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL) cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and 28.4 million DALYs), liver cancer (572000 deaths and 15.2 million DALYs), and stomach cancer (542000 deaths and 12.2 million DALYs). For women in 2017, the most common incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident cases), and colorectal cancer (819000 incident cases). The leading causes of cancer deaths and DALYs for women were breast cancer (601000 deaths and 17.4 million DALYs), TBL cancer (596000 deaths and 12.6 million DALYs), and colorectal cancer (414000 deaths and 8.3 million DALYs). Conclusions and Relevance: The national epidemiological profiles of cancer burden in the GBD study show large heterogeneities, which are a reflection of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. The GBD study can be used by policy makers and other stakeholders to develop and improve national and local cancer control in order to achieve the global targets and improve equity in cancer care.

AB - Importance: Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data. Objective: To describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning. Evidence Review: We used the GBD study estimation methods to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs). Results are presented at the national level as well as by Socio-demographic Index (SDI), a composite indicator of income, educational attainment, and total fertility rate. We also analyzed the influence of the epidemiological vs the demographic transition on cancer incidence. Findings: In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority of cancer DALYs came from years of life lost (97%), and only 3% came from years lived with disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL) cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and 28.4 million DALYs), liver cancer (572000 deaths and 15.2 million DALYs), and stomach cancer (542000 deaths and 12.2 million DALYs). For women in 2017, the most common incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident cases), and colorectal cancer (819000 incident cases). The leading causes of cancer deaths and DALYs for women were breast cancer (601000 deaths and 17.4 million DALYs), TBL cancer (596000 deaths and 12.6 million DALYs), and colorectal cancer (414000 deaths and 8.3 million DALYs). Conclusions and Relevance: The national epidemiological profiles of cancer burden in the GBD study show large heterogeneities, which are a reflection of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. The GBD study can be used by policy makers and other stakeholders to develop and improve national and local cancer control in order to achieve the global targets and improve equity in cancer care.

UR - http://www.scopus.com/inward/record.url?scp=85072768207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072768207&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2019.2996

DO - 10.1001/jamaoncol.2019.2996

M3 - Article

C2 - 31560378

AN - SCOPUS:85072768207

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

ER -